Disparities in Pediatric Rheumatic Diseases

Alisha M Akinsete1, Jennifer M P Woo2, Tamar B Rubinstein1

  • 1Division of Pediatric Rheumatology, Department of Pediatrics, Children's Hospital at Montefiore/Albert Einstein College of Medicine, 3415 Bainbridge Avenue, Bronx, NY 10467, USA.

Insights

Pediatric rheumatology patients facing social disadvantages experience worse health outcomes due to healthcare barriers. Addressing these disparities is crucial for improving care for all children with rheumatic diseases.

Area of Science:

  • Pediatric Rheumatology
  • Health Disparities Research
  • Health Services Research

Background:

  • Health and healthcare disparities are widespread in pediatric rheumatology, affecting marginalized populations based on race/ethnicity, socioeconomic status, and geography.
  • These disparities lead to increased disease severity, morbidity, mortality, reduced quality of life, and poor mental health outcomes.
  • Structural and institutional barriers, including limited access to quality healthcare, contribute significantly to these disparities.

Purpose of the Study:

  • To highlight the prevalence and impact of health and healthcare disparities in pediatric rheumatology.
  • To identify gaps in the existing literature regarding disparities in less-studied pediatric rheumatic diseases.
  • To emphasize the need for understanding disparity causes to inform policy and interventions.

Main Methods:

  • Literature review focusing on health and healthcare disparities in pediatric rheumatology.
  • Analysis of existing research to identify populations affected and outcomes.
  • Identification of research gaps concerning specific pediatric rheumatic diseases.

Main Results:

  • Socially disadvantaged and marginalized groups face significant health and healthcare disparities in pediatric rheumatology.
  • Juvenile idiopathic arthritis and childhood-onset systemic lupus erythematosus are the most studied conditions, with limited research on other rheumatic diseases.
  • Disparities are linked to factors like race/ethnicity, socioeconomic position, and geographic location.

Conclusions:

  • Persistent structural and institutional barriers impede equitable care for children with rheumatic diseases.
  • Further research is needed to address disparities across all pediatric rheumatic conditions.
  • Understanding the root causes of disparities is essential for developing effective policies and interventions to improve pediatric rheumatology care.

Related Concept Videos

Rheumatic Heart Disease I: Introduction01:23

Rheumatic Heart Disease I: Introduction

Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
87
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies01:22

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
114
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
23
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
53
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
22
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
21